REGENERON PHARMACEUTICALS, INC. (REGN): Results of Operations and Financial Condition

REGENERON PHARMACEUTICALS, INC. (REGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 1.01. Entry into a Material Definitive Agreement. On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“ Regeneron ” or the “ Company ”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“ Sanofi Biotechnol

Event · Earnings
Also in this documentGuidance · lower · $22M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 6, 2026, 11:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

The deal provides a sizable cash infusion and long‑term revenue upside, while the IPR&D charge slightly dents Q3 earnings.

02

Market read

New licensing agreement is a material corporate event likely to move Regeneron stock and influence biotech partnership sentiment.

03

What to watch

The $22 million IPR&D charge may depress near‑term earnings, and Sanofi's share of future profits could limit Regeneron's upside.

Relevance 8/10Novelty 8/10Timing: immediate filing today
AlphAI · Earnings readREGN · third quarter 2026 · ended September 30, 2026

Regeneron expects an acquired IPR&D charge in the third quarter 2026 and expands its Sanofi antibody collaboration through four new long-acting antibodies.

→Mixed quarter

The filing provides no finalized operating results, revenue, profitability, or cash-flow data. It discloses an expected acquired IPR&D charge affecting third-quarter GAAP and non-GAAP EPS alongside a collaboration amendment that includes an upfront payment and potential milestone payments.

EPS · non-GAAP
approximately $0.18

Key metrics

as reported
MetricValueq/qy/y
Acquired in-process research and development (IPR&D) charge, third quarter 2026, pre-taxotherapproximately $22 million––
Expected impact on GAAP net income per diluted share, third quarter 2026GAAPapproximately $0.18––
Expected impact on non-GAAP net income per diluted share, third quarter 2026non-GAAPapproximately $0.18––

What drove it

  • Sanofi will make an upfront payment to Regeneron of $1.0 billion pursuant to the Sixth Amendment.
  • Regeneron will be entitled to receive up to an additional $7.0 billion of payments in the aggregate upon achievement of certain development, regulatory, and commercial milestones with respect to the New Licensed Products.
  • Regeneron and Sanofi agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13.
  • Global profits realized on sales of New Licensed Products will be shared equally between Regeneron and Sanofi.
  • Development costs for licensed products under the Antibody LCA, including the New Licensed Products, will be shared equally by the parties.

Concerns

  • Third-quarter 2026 results have not been finalized and remain subject to financial statement closing procedures.
  • The expected acquired IPR&D charge is expected to negatively affect both GAAP and non-GAAP net income per diluted share.
  • Development costs in excess of a budget cap for all New Licensed Products will be Regeneron's responsibility, subject to certain rights to recoup excess costs in future years.
  • The filing does not report revenue, product sales, margins, operating income, net income, cash flow, cash, debt, or finalized EPS.

What to watch

  • Final third-quarter 2026 financial results and whether they differ from the preliminary unaudited estimates.
  • Recognition and financial presentation of the Sanofi upfront payment.
  • Progress of the initial global development plan for the IL-13 asset and development plans for the other New Licensed Products.
  • Whether Regeneron exercises its option to include lunsekimig or another Sanofi early development product in the collaboration.
  • Development spending relative to the budget cap for the New Licensed Products.

Analysis

This is not a full earnings release. Regeneron states that its third-quarter 2026 results have not been finalized and provides only a preliminary expected acquired IPR&D charge. The Company expects an acquired IPR&D charge of approximately $22 million on a pre-tax basis, with an expected negative impact of approximately $0.18 on each of GAAP and non-GAAP net income per diluted share. No revenue, product-sales, margin, operating-income, net-income, or cash-flow results are reported.

The principal disclosure is the Sixth Amendment to the Antibody LCA with Sanofi. The parties will co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies, while global profits from their sales will be shared equally. Sanofi will make an upfront payment to Regeneron of $1.0 billion, and Regeneron may receive up to an additional $7.0 billion upon specified development, regulatory, and commercial milestones.

The agreement extends Regeneron's development and U.S. regulatory role for the New Licensed Products, while Sanofi will lead commercialization and regulatory activities outside the United States. Development costs will be shared equally, but Regeneron will bear development costs above the budget cap for all New Licensed Products, subject to specified future recoupment rights. This allocation makes the scale and timing of development spending an important item for the finalized financial results and subsequent reporting.

The filing also gives Regeneron an asset-by-asset option, after certain ongoing clinical trials, to include Sanofi's Phase 2/3 asset lunsekimig and another Sanofi early development product. Exercising that option would require Regeneron to reimburse Sanofi for certain related development costs. Investors will need the final third-quarter release to assess the preliminary IPR&D charge in the context of operating performance and to obtain any accounting detail related to the collaboration payments.

Not in the filing

stated, not guessed
  • Total revenue and prior-period comparisons
  • Product revenue and segment revenue
  • Gross margin
  • Operating expenses
  • Operating income
  • GAAP net income
  • Non-GAAP net income
  • GAAP EPS excluding the stated expected IPR&D impact
  • Non-GAAP EPS excluding the stated expected IPR&D impact
  • Operating cash flow
  • Free cash flow
  • Cash and cash equivalents
  • Debt
  • Share repurchases
  • Dividends
  • Forward revenue guidance
  • Forward gross-margin guidance
  • Forward operating-expense guidance
  • Forward tax-rate guidance
  • Named executive quotes
  • The previous outlook covered the full year 2026 only, and this release reports the third quarter, so there is nothing comparable.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Regeneron filed an 8‑K reporting a material definitive agreement with Sanofi and preliminary Q3 financial impacts.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Regeneron disclosed a $1 billion upfront payment and up to $7 billion in milestones from a new licensing agreement with Sanofi, plus a $22 million IPR&D charge affecting Q3 earnings.

Expected impact

likely upward pressure as investors price in the $1 billion cash inflow and long‑term milestone upside.

Evidence & confidence

Large upfront cash and multi‑billion milestone structure are material and newly disclosed, prompting a re‑rating of Regeneron's pipeline valuation.

Market effects

Strengthens the biotech licensing and partnership landscape, may boost peers with similar collaboration models.

Positive for US biotech stocks; limited direct effect on European markets beyond Sanofi exposure.

Highlights growing cross‑border biotech collaborations, modest global macro impact.

Counterpoint

Milestone payments are uncertain; execution risk could outweigh the upfront cash, keeping the stock volatile.

Key entities

  • Regeneron Pharmaceuticals, Inc.

    US biotech firm entering a new licensing partnership with Sanofi.

  • Sanofi

    French pharmaceutical group partnering with Regeneron on antibody development.

Every REGN earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.